Biochemical and genetic risk factors for atherosclerosis in systemic lupus erythematosus

Egyptian Rheumatologist

Volumn 33, Issue 1, 2011, Pages 35-43

  Saadany, Hanan El ^a   El Sergany, Mervat ^a   Kasem, Elham ^a   El Batch, Manal M ^a   Zakaria, Soha S ^a   Mourad, Heba ^a   Moustafa, Timour ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Asymmetric dimethylarginine; Gene polymorphism; High sensitive CRP; Intima media thickness; Monocyte chemoattractant protein 1; SLE

Indexed keywords

ALANINE; C REACTIVE PROTEIN; GLYCINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN TARGETING; RESTRICTION MAPPING; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84878596019     PISSN: 11101164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejr.2010.11.001     Document Type: Article

References (49)

1. Kariuki S.N., Niewold T.B. Genetic regulation of serum cytokines in systemic lupus erythematosus. Translat Res 2010, 155(3):109-117.
2. Ghosh P., Kumar A., Kumar S., Aggarwal A., Sinha N., Misra R. Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus. Clin Rheumatol 2009, 28(11):1259-1265.
3. Koca S.S., Karaca I., Yavuzkir M.F., Daĝli N., Ozgen M., Ustündaĝ B., et al. Insulin resistance is related with oxidative stress in systemic lupus erythematosus. Anadolu Kardiyol Derg 2009, 9(1):23-28.
4. Haque S., Mirjafari H., Bruce I.N. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol 2008, 19(4):338-343.
5. Colombo B.M., Murdaca G., Caiti M., Rodriguez G., Grassia L., Rossi E., et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann NY Acad Sci 2007, 1108:121-126.
6. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 2010, 47(1):17-28.
7. Landim M.B.P., Casella Filho A., Chagas A.C.P. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics 2009, 64(5):471-478.
8. Yuasa S., Maruyama T., Yamamoto Y., Hirose H., Kawai T., Matsunaga Irie S., et al. MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res Clin Pract 2009, 86(3):193-198.
9. Rua Figueroa I., Arencibia Mireles O., Elvira M., Erausquin C., Ojeda S., Francisco F., et al. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 2010, 69(6):1136-1139.
10. Corrado E., Rizzo M., Coppola G., Fattouch K., Novo G., Marturana I., et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Theromb 2010, 17(1):1-11.
11. Aguilar F., González Escribano M.F., Sánchez Román J., Núñez Roldán A. MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 2001, 58(5):335-338.
12. Ito T., Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy 2003, 2(3):257-265.
13. Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009, 48(1):11-22.
14. Nyquist P.A., Winkler C.A., McKenzie L.M., Yanek L.R., Becker L.C., Becker D.M. Single nucleotide polymorphisms in monocyte chemoattractant protein-1 and its receptor act synergistically to increase the risk of carotid atherosclerosis. Cerebrovasc Dis 2009, 28(2):124-130.
15. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
16. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992, 35(6):630-640.
17. Sidhu P.S., Desai S.R. A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery. Brit J Radiol 1997, 70:85-89.
18. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003, 24(21):1912-1919.
19. Auer J., Berent R., Lassnig E., Eber B. C-reactive protein and coronary artery disease. Jpn Heart J 2002, 43(6):607-619.
20. Leonard E.J., Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990, 11(3):97-101.
21. Rovin B.H., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999, 259(2):344-348.
22. Manzi S., Agarwal S., Elliott J.R. Atherosclerosis risk factors in systemic lupus erythematosus. Curr Rheumatol Rep 2009, 11(4):241-247.
23. Cacciapaglia F., Zardi E.M., Coppolino G., Buzzulini F., Margiotta D., Arcarese L., et al. Stiffness parameters, intima-media thickness and early atherosclerosis in systemic lupus erythematosus patients. Lupus 2009, 18(3):249-256.
24. Sato H., Miida T., Wada Y., Maruyama M., Murakami S., Hasegawa H., et al. Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin Chim Acta 2007, 385(1-2):35-42.
25. El Magadmi M., Bodill H., Ahmad Y., Durrington P.N., Mackness M., Walker M., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004, 110(4):399-404.
26. Carotti M., Salaffi F., Mangiacotti M., Cerioni A., Giuseppetti G.M., Grassi W. Aterosclerosi nell'artrite reumatoide: ruolo dell'ecografia ad alta risoluzione nella valutazione dello spessore arterioso medio-intimale [Atherosclerosis in rheumatoid arthritis: the role of high-resolution B mode ultrasound in the measurement of the arterial intima-media thickness]. Reumatismo 2007, 59(1):38-49.
27. Del Sol A.I., Moons K.G., Hollander M., Hofman A., Koudstaal P.J., Grobbee D.E., et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam study. Stroke 2001, 32(7):1532-1538.
28. McMahon M., Hahn B.H. Atherosclerosis and systemic lupus erythematosus - mechanistic basis of the association. Curr Opin Immunol 2007, 19(6):633-639.
29. Valdivielso P., Gómez Doblas J.J., Macias M., Haro Liger M., Fernández Nebro A., Sánchez Chaparro M.A., et al. Lupus-associated endothelial dysfunction, disease activity and arteriosclerosis. Clin Exp Rheumatol 2008, 26(5):827-833.
30. Bultink I.E., Teerlink T., Heijst J.A., Dijkmans B.A., Voskuyl A.E. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity and organ damage in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64(9):1362-1365.
31. Sydow K., Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003, 4(4):41-51.
32. Boger R.H., Bode Boger S.M., Tsao P.S., Lin P.S., Chan J.R., Cooke J.P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000, 36(7):2287-2295.
33. Abou Raya A., Abou Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006, 5(5):331-337.
34. Barnes E.V., Narain S., Naranjo A., Shuster J., Segal M.S., Sobel E.S., et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005, 14(8):576-582.
35. Roh E.J., Lim J.W., Ko K.O., Cheon E.J. A useful predictor of early atherosclerosis in obese children: serum high-sensitivity C-reactive protein. J Korean Med Sci 2007, 22(2):192-197.
36. Olsen M.H., Christensen M.K., Hansen T.W., Gustafsson F., Rasmussen S., Wachtell K., et al. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. J Hypertens 2006, 24(4):655-661.
37. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Natoli E., Rollins B.J., et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999, 19(6):1518-1525.
38. Reckless J., Rubin E.M., Verstuyft J.B., Metcalfe J.C., Grainger D.J. Monocyte chemoattractant protein-1 but not tumor necrosis factor-alpha is correlated with monocyte infiltration in mouse lipid lesions. Circulation 1999, 99(17):2310-2316.
39. Brown K.S., Nackos E., Morthala S., Jensen L.E., Whitehead A.S., Von Feldt J.M. Monocyte chemoattractant protein-1: plasma concentrations and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 2007, 34(4):740-746.
40. Deo R., Khera A., McGuire D.K., Murphy S.A., Meo Neto J.de P., Morrow D.A., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors and subclinical atherosclerosis. J Am Coll Cardiol 2004, 44(9):1812-1818.
41. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010, 17(4):332-341.
42. Schepers A., Eefting D., Bonta P.I., Grimbergen J.M., de Vries M.R., van Weel V., et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 2006, 26(9):2063-2069.
43. Szalai C., Duba J., Prohaszka Z., Kalina A., Szabo T., Nagy B., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for Coronary Artery Disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001, 158(1):233-239.
44. Tucci M., Barnes E.V., Sobel E.S., Croker B.P., Segal M.S., Reeves W.H., et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004, 50(6):1842-1849.
45. Sánchez E., Sabio J.M., Callejas J.L., de Ramón E., Garcia Portales R., García Hernández F.J., et al. Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus. BMC Med Genet 2006, 7:48.
46. Tabara Y., Kohara K., Yamamoto Y., Igase M., Nakura J., Kondo I., et al. Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. Hypertens Res 2003, 26(9):677-683.
47. Buraczynska M., Bednarek Skublewska A., Buraczynska K., Ksiazek A. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients. Cytokine 2008, 44(3):361-365.
48. Lima G., Soto Vega E., Atisha Fregoso Y., Sánchez Guerrero J., Vallejo M., Vargas Alarcón G., et al. MCP-1, RANTES and SDF-1 polymorphisms in Mexican patients with systemic lupus erythematosus. Human Immunol 2007, 68(12):980-985.
49. Furuki K., Adachi H., Enomoto M., Otsuka M., Fukami A., Kumagae S., et al. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertens Res 2008, 31(6):1185-1189.